Across your portfolio, millions in EBITDA are stuck in unworked denials, uncontested underpayments, and aging AR. That’s EBITDA you already earned
End-to-end revenue cycle execution for PE portfolios. Denials managed. Underpayments recovered. AR optimized. No new hires. Outcome-based pricing.
ANKA inverts the traditional model. Deploy it across your portfolio for standardized revenue cycle execution. Outcome-based pricing ensures every dollar of margin improvement lands in EBITDA. No new hires required.
The linear FTE model is dead. Here’s what replaces it
McKinsey (Jan 2026): Agentic AI cuts RCM cost-to-collect by 30–60%. The operating leverage is now in execution, not headcount.
Revenue teardown for PE healthcare portfolios
Upload your portfolio data room. ANKA analyzes every company’s claims, denials, underpayments, and aged AR. See the aggregate recovery opportunity. Unworked denials. Missed underpayments. Recoverable aged AR. Dollar by dollar. By company. By payer. Sourced and modeled. One dashboard. Full portfolio visibility.
Need to start narrower? Single company assessment available — same rigor, smaller scope.
Your post-acquisition playbook
Day 1–30: assess
ANKA runs baseline assessment. Claims volume. Denial rate. Underpayment exposure. Aged AR. Current RCM cost structure. Staffing gaps identified. Recovery opportunity quantified.
Outcome: Clear picture of what’s broken and what’s worth fixing.
Day 30–60: connect
ANKA integrates with your EHR. Denial feeds configured. AR data flowing. Underpayment audit rules loaded (payer contracts uploaded). Automation workflows tested in sandbox. Your team trained. Exceptions defined.
Outcome: Systems connected. Automation ready. Zero manual work needed from your billing team to deploy.
Day 60–90: execute
ANKA goes live. Denials start flowing to execution. Appeals written and submitted. Underpayments recovered. Follow-ups automated. Your team handles exceptions only (the 10% that need human judgment).
Outcome: First revenue improvements visible. Denials moving to resolution. Collections momentum building.
Day 90+: measure & optimize
ANKA tracks every metric. Denial rate trending downward. AR days improving. Collection rate climbing. Underpayment recovery running (and accelerating as payer patterns are learned). Outcome SLAs measured weekly. Adjustments made automatically.
Outcome: Stable 30–50% cost-to-collect reduction. Repeatable across your entire portfolio.
What this means for your portfolio
A 5-company portfolio with $750M in annual revenue can reduce RCM costs by $900K–$1.5M without adding staff.
From unworked denials and underpayment recovery. Margin improvement flows to EBITDA.
One playbook. Multiple companies. Parallel deployment. Revenue impact visible in 60–90 days.
Recover underpayments first. Pay from what you find. Monthly base + outcome component on denial resolution.
Example portfolio: 5 healthcare companies. $750M combined revenue. Average 4% baseline collection leakage (standard for mid-market). Total leakage: $30M per year. ANKA’s 30–50% cost-to-collect reduction + collections improvement = $2–5M in annual EBITDA lift. From execution, not headcount.
What $852M in failed healthcare AI teaches us
- ✗ Promised to do “all back-office work”
- ✗ Built dashboards. Sent alerts. Showed insights.
- ✗ Required people to execute (you still needed the staff)
- ✗ Raised $852M on the promise
- ✗ Never delivered execution. Only reporting.
- ✗ Went bankrupt in 2024
- ✓ Does the work. Not the reporting.
- ✓ Appeal gets submitted. Not recommended for submission.
- ✓ Underpayment gets recovered. Not flagged for recovery.
- ✓ Your team handles exceptions only (what needs human judgment)
- ✓ We guarantee outcomes in the contract. Teeth on the guarantee.
- ✓ You pay only when results improve (or fixed fee with outcome SLAs)
The difference between AI that helps you do work and AI that does the work is everything.
Questions about portfolio deployment and outcomes
Can you really deploy ANKA across 5+ different healthcare companies at the same time?
Yes. We’ve done it. The deployment is parallel, not sequential. Week 1–2: Assessment across all companies (concurrent). Week 2–3: EHR integration (one per EHR type, then replicated). Week 4: Execution live across the entire portfolio. One playbook. Repeatable setup.
What if portfolio companies have different EHRs?
Standard. Most of our PE portfolios run 3–5 different systems. We integrate once per EHR type, then replicate the integration to every company using that system. No extra work. No extra cost. Deployment timeline doesn’t extend.
How does outcome-based pricing work across a portfolio?
Two options: (1) Contingency on underpayment recovery across the portfolio, or (2) Fixed base fee + performance component tied to denial rate reduction, AR days, and collection improvement SLAs. If companies miss targets, fees adjust down. If targets are beaten, you keep the upside.
What’s the minimum portfolio size for ANKA?
No minimum. We work with individual PE-backed companies (same model) and with portfolios of 10+. The playbook scales. Your operational leverage scales with it.
What happens if a portfolio company exits? Or we acquire a new one?
Exits: ANKA’s data and outcome history stay with you for valuation/due diligence. New acquisitions: ANKA’s already deployed at your other companies — you can add the new company to the same system in 2–3 weeks (assessment + integration + execution).
See your portfolio opportunity
ANKA runs a comprehensive assessment of your portfolio’s unworked denials, underpaid claims, and aged AR. Upload your data room. See the aggregate recovery opportunity. Every company. Every payer. Modeled out.
Start Your Complimentary AssessmentComplimentary for qualified organizations (10+ providers). One week turnaround. Full portfolio visibility.